Skip to Main Content
Try STAT+ TODAY
Trending:
Biotech
Health
STAT+
Pharmalot
The Readout

CAR-T’s big risks & an awkward insider trade

  • Damian Garde
  • Meghana Keshavan

By Damian Garde and Meghana Keshavan Aug. 23, 2016

Reprints
The READOUT
Alex Hogan/STAT

The Readout for August 23, 2016

About the Authors Reprints

Damian Garde

Damian Garde

National Biotech Reporter

Damian Garde covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast.

Meghana Keshavan

Meghana Keshavan

Biotech Correspondent

Meghana Keshavan covers biotech and contributes to The Readout newsletter.

How Tennessee is creating new opportunities for doctors trained…
How Tennessee is creating new opportunities for doctors trained outside the U.S.
Tired of ‘dead end’ approach, herpes patients mobilize to…
Tired of ‘dead end’ approach, herpes patients mobilize to demand government action
The 20 most Googled diseases
The 20 most Googled diseases
Regeneron targets obesity, a new microbiome deal, & comparing…
Regeneron targets obesity, a new microbiome deal, & comparing cancer drug costs
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries…
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries & regenerating heart tissue
Docs disagree with FDA on Aduhelm, Swiss giants pinch…
Docs disagree with FDA on Aduhelm, Swiss giants pinch pennies, & one SPAC makes it rain

Recommended Stories